Providing Targeted Cancer Diagnostics

Molecular Pathology Update

From 1 August 2016, the molecular profiling activities undertaken by UCL Advanced Diagnostics have been transferred to HCA Healthcare, part of HCA Inc. The laboratory has been renamed Sarah Cannon Molecular Diagnostics.

This change only effects the molecular profiling service; the UCL Advanced Diagnostics Laboratory offering clinical immune-histochemical / in-situ hybridization services continues to be run and owned by University College London (UCL).

Why has ownership changed?

The UCL Advanced Diagnostics Molecular Pathology Laboratory based in Shropshire House was created in 2013 in joint partnership between UCL and HCA International and has since become the UK’s largest provider of molecular profiling using next generation sequencing (NGS).

It is anticipated that this change in ownership and operations will allow more flexibility of investment and realisation of future development opportunities, ultimately increasing the breadth and depth of profiling services offered to customers.

Sarah Cannon Molecular Diagnostics is supported by Sarah Cannon, the global cancer institute of HCA, which offers integrated cancer services with access to cutting-edge therapies for patients across the United States and UK. The UK arm of The Sarah Cannon Research Institute, based in Harley Street, partners with leading pharmaceutical and biotech companies in cancer research; providing a gateway for patients to the latest clinical trials.

The lab will continue to be led by Dr Phil Bennett and his team at Ground Floor, Shropshire House, 1 Capper Street London, WC1E 6JA. Contact Phil on 020 3794 1920 or by email at info@sarahcannon-md.co.uk. New website: www.sarahcannon-md.co.uk